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Abstract
Background:  Chronic recurrent multifocal osteomyelitis (CRMO) is an inflammatory, non-
infectious osteopathy that affects predominantly patients ≤ 18 years of age. There is no uniformly
effective treatment. Our objective is to describe clinical, magnetic resonance imaging (MRI), and
bone resorption response to intravenous pamidronate in pediatric CRMO.
Methods: We report our prospectively documented experience with all CRMO patients treated
with pamidronate between 2003 and 2008 at a tertiary pediatric centre. Pamidronate was
administered as intravenous cycles. The dose of pamidronate varied among subjects but was given
as monthly to every 3 monthly cycles depending on the distance the patient lived from the infusion
center. Maximum cumulative dose was ≤ 11.5 mg/kg/year. Pamidronate treatment was continued
until resolution of MRI documented bone inflammation. Visual analog scale for pain (VAS) and bone
resorption marker urine N-telopeptide/urine creatinine (uNTX/uCr) were measured at baseline,
preceding each subsequent pamidronate treatment, at final follow-up, and/or at time of MRI
confirmed CRMO flare. MRI of the affected site(s) was obtained at baseline, preceding every 2nd
treatment, and with suspected CRMO recurrence.
Results: Nine patients (5 F: 4 M) were treated, with a median (range) age at treatment of 12.9
(4.5–16.3) years, and median (range) duration of symptoms of 18 (6–36) months. VAS decreased
from 10/10 to 0–3/10 by the end of first 3–day treatment for all patients. The mean (range) time
to complete MRI resolution of bone inflammation was 6.0 (2–12) months. The mean (confidence
interval (CI)) baseline uNTX/uCr was 738.83 (CI 464.25, 1013.42)nmol/mmol/creatinine and the
mean (CI) decrease from baseline to pamidronate discontinuation was 522.17 (CI 299.77,
744.56)nmol/mmol/creatinine. Median (range) of follow-up was 31.4 (24–54) months. Four patients
had MRI confirmed CRMO recurrence, which responded to one pamidronate re-treatment. The
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mean (range) uNTX/uCr change as a monthly rate from the time of pamidronate discontinuation
to flare was 9.41 (1.38–19.85)nmol/mmol/creatinine compared to -29.88 (-96.83–2.01)nmol/mmol/
creatinine for patients who did not flare by the time of final follow-up.
Conclusion: Pamidronate resulted in resolution of pain and MRI documented inflammation in all
patients. No patient flared while his/her uNTX/uCr remained suppressed. We propose that
pamidronate is an effective second-line therapy in persistent CRMO.
Background
Chronic recurrent multifocal osteomyelitis (CRMO) is an
auto-inflammatory osteopathy that predominantly affects
children [1-3]. It is characterized by bone pain, soft tissue
swelling and osteolysis. SAPHO syndrome (synovitis,
acne, pustulosis, hyperostosis and osteitis) includes simi-
lar bony lesions, and the dermatologic manifestations
may be absent in childhood [4]. A recent series suggests
that unifocal and/or non-recurrent non-bacterial osteo-
myelitis may represent different levels of severity within
the same clinical spectrum, and a new classification has
been proposed to include all of these disorders under the
umbrella term of chronic non-bacterial osteomyelitis
(CNO) [5]. Within CNO, the existing entity of CRMO rep-
resents the more severe end of the spectrum [5]. In this
manuscript, the term CRMO is retained to describe this
subgroup of CNO patients.
Although majority of patients with CRMO have resolu-
tion of symptoms post-pubertally, the bone pain in active
disease is severe [6-9]. In addition, long-term studies
reveal that up to a quarter of patients have persistent dis-
ease, with risk for permanent bony deformities, poorer
quality of life, and difficulty in achieving vocational goals
[1,2,10,11]. There is no cure, and the goal of management
is effective pain control [1,2]. No single agent has proven
to be consistently effective, although analgesics, nonster-
oidal anti-inflammatory agents (NSAIDs) [5,12], sul-
fasalazine, methotrexate, corticosteroids and infliximab
have all been tried [3]. There is a need to develop new
therapies for treatment resistant patients.
Histology [6,12,13] reveals inflammatory changes, and
increased osteoclasts and bone resorption characterize
early lesions. Plain radiographs of early CRMO document
osteolytic lesions with periosteal reaction [9,11-13]. Mag-
netic resonance imaging (MRI) [14] is a non-invasive
imaging modality that is highly sensitive to active and
remitted inflammatory lesions in bone and soft tissues in
CRMO [14,15]. Active lesions occur with increased signal
intensity on short tau inversion recovery (STIR) or fat-sat-
urated T2-weighted images and decreased signal intensity
on T1-weighted images, consistent with inflammation
[15]. Conversely, resolved CRMO is reflected by no signs
of inflammation by MRI [5].
Because bisphosphonates inhibit bone resorption, have
pain modifying effect and demonstrate anti-inflammatory
action [3], they seemed excellent candidates for use in
CRMO. In year 2003, when our first patient was treated,
there were several reports of beneficial effect of bisphos-
phonates in adult patients with inflammatory osteitis,
such as symphysitis pubis and ankylosing spondylitis
[16,17], and in non-inflammatory pediatric bone disor-
ders, such as osteogenesis imperfecta [18] and polyostotic
fibrous dysplasia of the bone [19]. In addition, there was
one existing description in an abstract form of successful
use of pamidronate for rapid pain relief in a pediatric
patient with long-standing CRMO [20]. These encourag-
ing reports prompted us to pursue pamidronate for those
patients with persistently active CRMO despite conven-
tional treatment.
Urinary N-telopeptide/urine creatinine (uNTX/uCr) is a
marker of collagen-1 breakdown. It is traditionally used to
monitor treatment response to bisphosphonates in adult
patients with bone diseases characterized by accelerated
bone turnover, such as Paget's disease of bone [21,22]. It
has not been previously studied in pediatric inflammatory
osteopathies.
We present our clinical experience using pamidronate in
nine children with CRMO, in whom we prospectively col-
lected data on clinical features, pain, MRI and uNTX/uCr
response.
Methods
Patients
CRMO was diagnosed in 17 children from 2003 to 2008
at our tertiary care hospital. The diagnosis of CRMO was
made based on the following critera: (1) ≥ 2 typical bony
lesions (osteolysis with surrounding sclerosis on conven-
tional radiographs); (2) duration ≥ 6 months; (3) typical
histologic features (acute/chronic inflammation) on bone
biopsy; (4) and age < 18 years at diagnosis [12]. Eight chil-
dren responded to NSAIDs and were not considered for
pamidronate treatment. Sulfasalazine and/or prednisone
were offered after NSAID failure. All but one family
declined these medications. The reasons for the families'
reluctance to proceed with these other medications
included: 1) the already significant functional disability ofPediatric Rheumatology 2009, 7:2 http://www.ped-rheum.com/content/7/1/2
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the child; 2) concern for known side effects of especially
prednisone; and 3) pre-existing allergy to sulfasalazine. In
total, 9 patients continued to have severe pain, functional
limitations, and significant school/day-care absences
despite treatment with NSAIDs, analgesics, opioids, and/
or sulfasalzine and prednisone, and were offered pamidr-
onate (Table 1).
Treatment
Pamidronate was administered as intravenous cycles.
Patients received 1 mg/kg/day (maximum 60 mg/day) for
all but the very first infusion, which was 0.5 mg/kg/day.
The first 2 male patients received a 3-day treatment once
monthly. In subsequent patients, the treatment plan con-
sisted of an initial 3-day treatment, followed by either 1-
day treatment monthly, or 3-day treatment every 3
months, with a maximum cumulative dose of no more
than 11.5 mg/kg/year. The different treatment frequencies
were used to accommodate families who had to travel
long distances to the hospital. A 1-day pamidronate treat-
ment was repeated (1 mg/kg/day, with maximum dose of
60 mg/day) in cases of MRI-confirmed CRMO flare. It was
explained to all families that the treatment was off-label.
Patients were counseled for potential side effects, includ-
ing fever and myalgia, and after year 2006 – when cases of
osteonecrosis of the jaw were reported in adult patients
who were treated with bisphosponates – for the possibil-
ity for osteonecrosis of the jaw [23]. All parents/patients
gave consent to treatment with pamidronate. The patients'
calcium and Vitamin D intakes were maintained at 800–
1000 mg of elemental calcium and 400 IU of Vitamin D
daily. NSAIDs were discontinued two weeks prior to
pamidronate treatment. NSAID use was permitted in case
of suspected CRMO flare.
Clinical measures
"Pain" was recorded at baseline, at each pamidronate
treatment and at potential CRMO recurrence using a 10-
cm visual analog scale, anchored by "severe pain" and "no
pain". Patients' height was measured at baseline, and at
each follow-up.
Extra-osseous manifestations
Data was collected regarding extra-osseous manifestations
that can be seen in association with CRMO, including der-
matologic manifestations (acne, palmoplantar pustulosis
and psoriasis), synovitis, and inflammatory bowel dis-
ease.
Magnetic resonance imaging (MRI)
Bone and soft tissue inflammation in active CRMO was
confirmed by MRI, which was obtained at base-line and
prior to every 2nd treatment. MR images were acquired
from clinical Siemens 1.5 T scanners (Erlagen, Germany).
Multiple spin-echo T1-weighted images, fat-saturated T2-
weighted images (T2 FS) and post-gadolinium fat-satu-
rated T1-weighted images were routinely obtained. Short-
tau inversion recovery (STIR) images were obtained in
some patients instead of T2 FS, and regarded as equivalent
to T2 FS images. Once there was over 90% improvement
in inflammation, pamidronate was discontinued. In case
of suspected flare, MRI was repeated within 4 weeks of
symptom recurrence. The improvement or progression of
lesions was quantified in lesion volume measured on
multi-plane MR images, using either STIR or T2 FS images.
Laboratory measurements
Bone resorption was assessed by measurement of urinary
cross-linked N-telopeptides of type I collagen related to
creatinine (uNTX/uCr, in nmol/mmol/creatinine) by
enzyme-linked immunoabsorbent assay (Osteomark;
Ostex, Seattle, WA, USA) using the second void sample of
the morning. Each patient was compared to age and sex
specific uNTX/uCr ratios for healthy boys and girls [24].
UNTX/uCr was measured: a) just prior to the first pamid-
ronate treatment; b) on day 3 of the first treatment; c) pre-
ceding each subsequent treatment; d) at time of
confirmed CRMO flare; or e) at time of final follow-up for
those patients who did not flare during the study period.
Serum alkaline phosphatase (a marker for bone forma-
tion), erythrocyte sedimentation rate (ESR), and complete
blood count (CBC) were measured at baseline and at
monthly intervals during pamidronate treatment. C-reac-
tive protein (CRP) was not routinely measured. All labo-
ratory tests were repeated at time of suspected CRMO
flare. Serum calcium was measured just preceding each
infusion, and one hour after completion of infusion to
monitor for possible hypocalcemia which can be seen as
a side effect of bisphosphonate infusion.
Histology
All patients had a bone biopsy prior to diagnosis of
CRMO to exclude malignancy or infectious osteomyelitis.
Results
Nine patients (five female and four male) were treated
with pamidronate (Tables 1, 2). The median (range) age
at pamidronate treatment was 12.9 (4.5–16.3) years, and
the median (range) of duration of symptoms was 18 (6–
36) months. Median (range) duration of follow-up after
the first dose of pamidronate was 31.4 months (24–54)
(Table 2).
The first male and the first female patients are described in
the text, and the rest in the tables and figures.
Patient 1
This 16-year-old boy had severe bone pain, involving
sequentially right clavicle, left sacrum and right sacrum
over preceding 36 months. HLA-B27 was negative. APediatric Rheumatology 2009, 7:2 http://www.ped-rheum.com/content/7/1/2
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Table 1: Baseline characteristics of study patients with CRMO.
Total number of patients 9
Sex (F:M) 5:4
Age at pamidronate treatment (y)* 12.9 (4.5–16.3)
Duration of symptoms before IVP (m)* 18 (6–36)
HLA-B27 positive (n) 3/9
VAS for pain pre-IVP (scale 0–10) 10/10 for all patients
Functional limitation pre-pamidronate
Prolonged school/daycare absences (n) 9/9
Hospitalized for pain management (n) 4/9
Limited use of upper limb (n) 3/9
Difficulty weight bearing (n); requiring crutches (n) 5/9; 2/9
Bedridden from spinal/leg pain (n) 2/9
Extra-osseus manifestations at baseline
Psoriasis/palmoplantar pustulosis/acne 0/9
Synovitis/inflammatory bowel disease 0/9
Number of patients with elevated ESR at baseline 6/9
ESR value (range) at baseline (normal < 10 mm/Hg)* 23.7 (3–52 mm/Hg)
Bone involvement pre-IVP as documented by MRI
Number of affected sites* 3.5 (2–9)
Clavicle (n) 2/9
Sacroiliac joint region (n) 2/9
Distal fibula (n) 2/9
Distal femur (n) 4/9
Vertebrae (n; range for number of involved vertebrae) 2/9 (3–9)
Distal tibia (n) 2/9
Proximal humerus (n) 1/9
Distal radius (n) 1/9
Clinically evident adjacent soft tissue swelling pre-pamidronate
Number of patients 5/9
Bone histopathology
Number of patients with bone biopsies** (n) 9/9
Active inflammation only (n) 5/9
Chronic inflammation only (n) 1/9
Active and chronic inflammation (n) 3/9
Increased bone resorption and osteoclasts (n) 1/9
Necrotic bone (n) 2/9
Reactive new bone (n) 1/9
Previous treatment pre-IVP
Nonsteroidal anti-inflammatory drugs (n)*** 9/9
Sulfasalazine (50 mg/kg/day) (n) 1/9
Prednisone (oral, 10 mg/day) (n) 1/9
Codeine (n) 9/9
Fentanyl (n) 3/9
Morphine (n) 1/9
Ketorolac (n) 1/9
Amitriptyline (n) 1/9
Surgical courettage (n) 2/9Pediatric Rheumatology 2009, 7:2 http://www.ped-rheum.com/content/7/1/2
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biopsy of the right clavicle showed minimal inflamma-
tion. CRMO was diagnosed when he developed MRI doc-
umented involvement of the ileum adjacent to each
sacroiliac joint (SIJ). Despite prolonged physiotherapy,
analgesia, naproxen (15 mg/kg/day), sulfasalazine (2
grams/day), fentanyl, and prednisone (10 mg/day for 5
days, resulting in psychosis) he had incapacitating pain in
the right sacrum for 7 months preceding pamidronate
treatment. He was unable to bend forward, walk without
a limp, run, or sit for the duration of a regular school class.
He received 2 monthly pamidronate treatments. The first
dose resulted in complete pain resolution on VAS. MRI of
the right sacrum had normalized by 6 weeks (Figure 1).
UNTX/uCr decreased from 165 to 28.3 nmol/mmol/creat-
inine after the first treatment. He required two re-treat-
ments, 18 and 27 months following the first treatment for
MRI confirmed flare (Figure 1), with complete clinical
and MRI response. At each flare, uNTX/uCr had increased
again (170.2 and 120 nmol/mmol/creatinine, respec-
tively). He remains clinically well at 54 month follow-up.
CRMO = chronic recurrent multifocal osteomyelitis.
*Data is represented as median (range).
** The tissues derived from these biopsies were fixed in neutral-buffered formalin, decalcified with 8% formic acid, and processed routinely with 
paraffin embedding. These biopsies were performed at the initial presentation with bone pain to rule out infection/malignancy.
*** Nonsteroidal anti-inflammatory drugs included the following: naproxen sodium [up to 15 mg/kg/day], celecoxib [up to 200 mg/day], ibuprofen 
[up to 10 mg/kg/dose 4 times daily]
y = years.
m = months.
VAS = visual analogue scale for pain.
n = number of patients.
ESR = erythrocyte sedimentation rate.
IVP = intravenous pamidronate.
Table 1: Baseline characteristics of study patients with CRMO. (Continued)
Table 2: Data on pamidronate treatment, MRI response, MRI confirmed CRMO relapse, and follow-up
IVP dosing frequency
One day monthly (n) 6/9
Three day cycle every 3 months (n) 3/9
Cumulative dose of pamidronate in mg/kg/year* 5.0 (4.5–9.5)
Time to > 90% MRI signal resolution after initial treatment (m)* 6.0 (2–12)
Number of IVP cycles required for > 90% MRI signal resolution* 5 (2–10)
Number of patients with clinical resolution of adjacent soft tissue swelling 5/5
Side effects from IVP
Myalgia and fever with first dose (n) 4/9
Osteonecrosis of the jaw (n) 0/9
Duration of follow-up after first IVP (m)* 31.4 (24–54)
Number of patients who relapsed 4/9
Time from first IVP to relapse (m)* 12.3 (12–18)
Time to >90% MRI signal resolution after repeat IVP treatment for CRMO relapse (m) 2 (for all patients)
Extra-osseus manifestations during follow-up
Psoriasis/palmoplantar pustulosis/acne 0/9; 0/9; 1/9
Synovitis/inflammatory bowel disease 0/9; 0/9
*Data presented as median (range).
MRI = magnetic resonance imaging.
IVP = intravenous pamidronate treatment.
n = number of patients.
m = months.Pediatric Rheumatology 2009, 7:2 http://www.ped-rheum.com/content/7/1/2
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Patient 2
This 11-year-old girl had severe bone pain affecting
sequentially the left and right femurs over a 13-month
period, associated with soft tissue swelling. Her initial
presentation involved the left femur only, and malignancy
or osteomyelitis was suspected. Left femoral biopsy
revealed acute inflammation. She was started on
parenteral cloxacillin, although her cultures were nega-
tive.
CRMO was diagnosed 7 months later when the right
femur became involved despite ongoing treatment with
cloxacillin. Pre-pamidronate radiographs revealed sclero-
sis and osteolytic lesions in both femurs, with periostitis
in the left distal femur, corresponding to hot-spots on
bone-scan (Figure 2). She was HLA-B27 positive. She was
unable to walk unassisted despite a prolonged course of
naproxen (15 mg/kg/day) and codeine. The family
declined corticosteroids and sulfasalazine.
She received a total of three every 3-monthly pamidronate
treatments. VAS for pain resolved completely by day 3 of
the first treatment, accompanied by decrease in the soft
tissue swelling. MRI of both distal femurs at baseline doc-
umented bone inflammation (Figure 2). MRI signal
abnormalities normalized by the 3rd treatment, when
pamidronate was discontinued (Figure 2). To date, she
has required one further course of pamidronate for MRI
Imaging data of sacral involvement by CRMO in patient 2, a 16-year-old boy Figure 1
Imaging data of sacral involvement by CRMO in patient 2, a 16-year-old boy. (A) Pre-treatment imaging: Coro-
nal STIR MRI images reveal increased T2 signal in the ilium adjacent to the right sacroilial joint (SIJ), consistent with inflamma-
tion. (B) Imaging 2 months after initiation of pamidronate: Abnormal signal on coronal STIR has resolved. (C) 
Imaging at clinical relapse: Coronal STIR MRI image reveals increased T2 signal in the ilium adjacent to the left SIJ, consist-
ent with inflammation. The previously affected right ilium demonstrates no abnormal signal. (D): Imaging 2 months post 1 
day pamidronate retreatment: Previously demonstrated abnormal signal on coronal STIR is no longer seen.Pediatric Rheumatology 2009, 7:2 http://www.ped-rheum.com/content/7/1/2
Page 7 of 14
(page number not for citation purposes)
confirmed new CRMO lesion in the right sacrum at 14
months following the first treatment, with complete pain
resolution the day after. The abnormal MRI signal
resolved by 2 months following re-treatment (Figure 2).
The uNTX/uCr decreased from 1361.0 to 395.4 nmol/
mmol/creatinine by day 3 of first treatment. It had
increased to 504.0 nmol/mmol of creatinine at the time of
CRMO flare. She remains clinically well at 39-month fol-
low-up.
Other data
Clinical measurements
Pain, function, and day-care/school absences (Table 2)
All patients had significant and sustained pain relief fol-
lowing pamidronate, with a decrease in VAS from 10/10
Imaging data of CRMO involving both distal femurs in patient 2, an 11-year-old girl Figure 2
Imaging data of CRMO involving both distal femurs in patient 2, an 11-year-old girl. (A-E) Pre-treatment imag-
ing: (A) Pre-treatment technetium99nuclear bone scan demonstrates abnormal uptake in both distal femurs with more promi-
nent changes on the left (arrow). (B-C) Anterior-posterior radiographs of both distal femurs demonstrate ill-defined areas of 
sclerosis (arrows) mixed with small focal lucent areas. Periosteal reaction is noted on the left side. (D) Coronal STIR MRI 
images obtained 4 months after the bone scan reveal increased signal in the right femur. The left femur reveals post-opera-
tional changes on the site of previous bone biopsy (arrow). (E) Post-gadolinium fat-saturated T1 weighted image shows marked 
enhancement of the right distal femoral lesion, with post-operational changes in the left femur. (F-G) Imaging 10 months 
after initiation of pamidronate: Complete resolution of the right femoral lesion is demonstrated on STIR image (F) and 
post-gadolinium fat-saturated T1 weighted image (G). (H) Imaging at clinical relapse: Coronal STIR MRI images reveal 
increased T2 signal in the right aspect of the sacrum, consistent with inflammation. (I): Imaging 2 months post 1 day 
pamidronate retreatment: Previously demonstrated abnormal signal on coronal STIR has resolved (arrow).
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to 0–3/10 after the first treatment. Each patient recovered
full function of the areas affected by CRMO, returned to
daycare/school within 1 week after the first treatment, and
has not had further absences due to CRMO related pain.
A total of 5 patients developed recurrence of pain 12–18
months following the first pamidronate dose, unrespon-
sive to NSAIDs. MRI confirmed CRMO relapse in four
patients and revealed non-CRMO etiology for the remain-
ing patient (vertebral compression fracture from spinal
CRMO). All four patients responded to one-day pamidro-
nate re-treatment with complete pain resolution.
Extra-osseous manifestations
One of the patients developed moderate acne at age 17
years, after completion of pamidronate. No patient devel-
oped psoriasis, palmoplantar pustulosis, synovitis, or
inflammatory bowel disease during the follow-up period.
Magnetic resonance imaging (Table 2, Figures 1, 2, 3, 4)
Base line MRI confirmed inflammatory lesions in all
patients, with decreased T1 signal, increased T2 signal,
and post-gadolinium enhancement in affected bone and/
or soft tissues (Table 2). The abnormal signal improved
dramatically after the first treatment, with further
improvement with subsequent treatments. The mean time
for > 90% resolution of MRI signal abnormality was 6.0
months. The MRI abnormalities following re-treatment
for four patients with CRMO flare resolved within 2
months.
Imaging data of spinal and sacral CRMO lesions in a 10-year old girl Figure 3
Imaging data of spinal and sacral CRMO lesions in a 10-year old girl. (A-C). Pre-treatment sagital (A and B) 
and axial (C) MRI. (A) STIR sequence and (B and C) post-gadolinium T1-weighted sequence reveal abnormal signal in verte-
bral bodies of T10, T11, and S1 (arrows), as well as in sacral ala (arrow). (D-F). Post-treatment (5 months after initia-
tion of pamidronate) MRI using the same technique as (A-C): Complete resolution of the previously seen abnormal signal.Pediatric Rheumatology 2009, 7:2 http://www.ped-rheum.com/content/7/1/2
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In addition to figures 1, 2 which show the effects of
pamidronate in our first male and first female patients,
figures 3, 4 demonstrate effects of pamidronate on diag-
nostic imaging of CRMO involving spine, sacrum, and
clavicle. Figure 3 depicts MRI appearance of CRMO
involving spine and sacral ala in a 10-year old girl at base-
line and following pamidronate, revealing eventual reso-
lution of bone marrow edema of all affected sites. Figure
4 demonstrates characteristic radiographic appearance of
active CRMO involving a clavicle, and illustrates the
sequence of abnormal MRI signal resolution following
pamidronate. The base line MRI reveals robust soft tissue
inflammation in addition to bone marrow edema, not
evident on plain radiograph. The soft tissue edema
resolved much more rapidly than the bone marrow
edema, but eventually both resolved completely.
Laboratory measurements
UNTX/uCr (Figure 5)
Baseline uNTX/uCr values were within the 25th to 75th per-
centiles of age-expected range for five out of nine patients,
and two females and two males had values above the 75th
percentile. The mean (confidence interval (CI)) pre-first
pamidronate treatment uNTX/uCr was 738.83 (CI
Imaging data of CRMO lesion involving left clavicle in a 7-year old girl (A) Figure 4
Imaging data of CRMO lesion involving left clavicle in a 7-year old girl (A). Pre-treatment imaging. Plain radio-
graph of the left clavicle demonstrates periosteal new bone formation (arrow). (B-C). Pre-treatment MRI: (B) Axial (fat-
saturated, T2-weighted) and (C) post gadolinium MRI: Hyper-intense T2 signal with post-contrast enhancement is seen within 
the clavicle (arrow) with marked soft tissue inflammation (arrow). (D-E). Post-treatment MRI (5 months after initiation 
of treatment with pamidronate) with the same technique as B and C, respectively. The intra-osseous abnormal signal has 
significantly improved, and marked soft tissue abnormality has almost completely resolved. (F-G). Post-treatment MRI (8 
months after initiation of treatment with pamidronate) with the same technique as B and C, respectively, reveals com-
plete resolution of the intra-osseous abnormal signal.Pediatric Rheumatology 2009, 7:2 http://www.ped-rheum.com/content/7/1/2
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464.25, 1013.42)nmol/mmol/creatinine and the mean
(CI) decrease in uNTX/uCr after the first treatment was
440.99 (CI 246.33, 635.65)nmol/mmol/creatinine. The
mean (CI) decrease in uNTX/uCr from baseline to discon-
tinuation was 522.17 (CI 299.77, 744.56)nmol/mmol/
creatinine. The mean (range) uNTX/uCr change as a
monthly rate from the time of pamidronate discontinua-
tion to flare for patients with CRMO relapse was 9.41
(1.38–19.85)nmol/mmol/creatinine per month com-
pared to -29.88 (-96.83–2.01)nmol/mmol/creatinine per
month for patients who did not flare by the time of final
follow-up.
Urinary N-telopeptide/urinary creatinine ratio (uNTX/uCr) in girls (upper panel) and in boys (lower panel) Figure 5
Urinary N-telopeptide/urinary creatinine ratio (uNTX/uCr) in girls (upper panel) and in boys (lower panel). Data 
is shown for each individual patient prior to the first intravenous pamidronate treatment (IVP); just after the first IVP; at the 
time of pamidronate discontinuation; and either at the time of last follow-up for patients who did not flare or at the time of 
CRMO flare. Continuous lines represent the 75th (top), 50th (middle), and 25th (bottom) percentile, respectively, of the reference 
range for healthy subjects [24].Pediatric Rheumatology 2009, 7:2 http://www.ped-rheum.com/content/7/1/2
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Other laboratory measurements (Table 1)
Apart from mildly elevated ESR at baseline in 6 patients
all other laboratory markers were unremarkable. Three
patients out of nine were HLA-B27 positive. No patient
had hypocalcemia with pamidronate infusions.
Histopathology (Table 1)
All pre-treatment bone biopsies demonstrated inflamma-
tion, and one demonstrated increased osteoclasts with
bone resorption. No patient had a repeat bone biopsy fol-
lowing pamidronate.
Linear growth
Growth velocity was maintained at ≥ 5 cm/year for all
patients whose epiphyses were not closed by the first
pamidronate treatment (data not shown).
Secondary effects of pamidronate (Table 1)
Four patients developed fever and myalgia with the first
pamidronate dose. No osteonecrosis of the jaw was
observed.
Discussion
We have presented data on clinical and MRI response to
pamidronate in nine pediatric patients with persistent
CRMO. Dramatic pain relief, followed by an impressive
improvement in bone inflammation was documented in
all patients. Four children had MRI confirmed relapses 12
– 18 months following pamidronate treatment, with
prompt response to re-treatment.
Although the individual course of CRMO can vary, long-
term studies emphasize the potentially debilitating nature
of this condition. A 2007 review of 39 pediatric CRMO
patients by Jansson et al reported a median disease dura-
tion of 21 months, with 51% of patients having ongoing
active disease in the preceding 18 month period [3]. Other
studies have revealed disease duration for up to 14–25
years [1,2,15]. Huber et al reporting on 23 Canadian
patients [2] and Catalano-Pons et al reporting on 40
patients from a multi-center study in France[25] confirm
that for patients with persistent disease, the adverse effects
can extend into future and include: 1) poorer quality of
life[2]; 2) risk for bone abnormalities (kyphosis, vertebral
fractures, and limb length discrepancy); and 3) potentially
worse vocational outcome [1-4,9,25,26]. Even those
patients who eventually recover have significant pain dur-
ing CRMO flares, with adverse effect on general well-
being. Although anti-inflammatory medications and sur-
gery are effective for some patients, there is a need to find
effective treatment for refractory cases.
Pamidronate was chosen because of beneficial reports in
one pediatric patient with CRMO [20] and in several adult
patients with inflammatory osteitis [16,17,27]. During
our study period, other reports in the literature emerged,
confirming the efficacy of bisphosphonates for pain relief
in pediatric and adult onset SAPHO syndrome [4,21], in
pediatric patients with chronic inflammatory lesions of
the mandible [28], and in further cases of CRMO [29,30].
According to the new proposed classification of chronic
non-bacterial osteomyelitis (CNO) as an umbrella term
for CRMO, SAPHO syndrome, and unifocal/non-recur-
rent non-bacterial osteomyelitis [5], the equally beneficial
effects of bisphosphonates in these disorders seem to be
supportive of a shared pathogenesis.
Pathogenesis of CRMO/CNO continues to be poorly
understood. It is not known what triggers the initial epi-
sode, and why some patients have more persistent disease
than others. However, both local and systemic increase of
tumor necrosis factor alpha (TNF-α) has been docu-
mented in active CRMO/CNO [3]. In keeping with this
observation, beneficial effects of anti-TNF agents have
been reported in a few patients each with CRMO [31],
SAPHO syndrome [32], and inflammatory bowel disease
related CRMO [33]. Indeed, some of the anti-inflamma-
tory effects of bisphosphonates are proposed to be sec-
ondary to their ability to suppress proinflammatory
cytokines, such as TNF-α, interleukin (IL)-6, and IL-1 [16].
The dosing and scheduling regimen for pamidronate in
our study was adapted empirically from the schedule used
in treating osteogenesis imperfecta [18]. Although we had
designed our study to allow for a maximum cumulative
pamidronate dose of 11.5 mg/kg/year, no patient
required this maximum dose.
The most striking clinical observation was rapid pain
relief within 48 hours following the first pamidronate
treatment, regardless of the location of CRMO lesions.
The effective pain relief following pamidronate has now
been observed in a variety of pediatric CNO disorders. The
1999 abstract by Seibel et al was the first to document dra-
matic pain relief following pamidronate in an adolescent
boy with a 6-year history of intermittently active CRMO
[20]. This patient received 30 mg of IV pamidronate, with
complete pain resolution within 4 days. His radiographs
gradually improved over one year, although they did not
completely normalize. The beneficial effect of pamidro-
nate in childhood onset SAPHO syndrome is illustrated
by Kerrison et al who reported dramatic pain relief in 7
pediatric patients following an initial dose of pamidro-
nate [4]. In keeping with the observation that some chil-
dren with SAPHO syndrome may lack dermatological
features, these authors included three patients with bone
lesions only, and who therefore were similar to our
CRMO patients. The skin lesions in the remaining
patients consisted of psoriasis/pustular psoriasis. The
dose of pamidronate varied between a maximum of 30–Pediatric Rheumatology 2009, 7:2 http://www.ped-rheum.com/content/7/1/2
Page 12 of 14
(page number not for citation purposes)
60 mg/day, given as 3-day cycles. The frequency of pamid-
ronate cycles was determined by symptom recurrence.
Five patients had clinical relapse of osteitis, which
responded to repeat pamidronate in all patients. The
authors did not comment on dermatological response fol-
lowing pamidronate. Finally, complete pain resolution
and decrease in adjacent soft tissue swelling was docu-
mented by Compeyrot-Lacassagne et al in two pediatric
patients with chronic inflammatory lesions of the mandi-
ble within one week of pamidronate [28]. Similar to Ker-
rison's and our series, both of these patients had
recurrence of inflammatory osteitis, 6 and 17 months
after the initial treatment. CT scan together with clinical
features and laboratory measurements was used to moni-
tor disease activity.
Although the rapid pain relief after bisphosphonates in
multiple bone disorders is well documented, its etiology
remains incompletely understood. Ghilardi et al have
studied osteolytic bone lesions in malignancies, and sug-
gest that overactive osteoclasts induce acidic environ-
ment, which allows bone resorption by osteoclasts,
contributing to the bone destruction and damage to pri-
mary afferent fibers [34]. Bisphosphonates neutralize the
nociceptive acidic environment rapidly by inactivating
osteoclasts. This mechanism could explain the rapid pain
relief in our patients. The prompt improvement in soft tis-
sue swelling adjacent to bone lesions, which was observed
in several of our CRMO patients, most likely reflects the
anti-cytokine effects of pamidronate.
Compared to the above reports on effective analgesic
effects of pamidronate in diverse pediatric CNO disorders,
our study was unique in that all patients had correlating
MR images to document bone inflammation and its reso-
lution at pre-determined time points [4,20]. The advan-
tage of obtaining MRI at baseline and during follow-up is
multifold. MRI is extremely sensitive in detecting bone
marrow edema and soft tissue edema that are present in
inflammatory processes such as CRMO. It is more sensi-
tive indicator of disease activity than the lytic changes seen
on plain radiography. It is especially helpful in evaluating
lesions that are difficult to visualize by plain radiography,
such as spine and pelvis [35]. At baseline, all patients
demonstrated bone and/or soft tissue inflammation by
MRI. MRI improved remarkably after the first pamidro-
nate treatment, with further resolution with subsequent
treatments, supporting the proposed anti-inflammatory
role of bisphosphonates [4,27]. Because CRMO can result
in pain from non-inflammatory bone changes such as ver-
tebral body compression fractures from spinal CRMO [3],
we recommend a repeat MRI assessment in cases of sus-
pected flare, particularly if repeat treatment with pamidr-
onate is contemplated.
In this study we show for the first time data on bone
remodeling markers in pediatric CRMO patients. In adult
onset SAPHO syndrome, increased levels of serum osteo-
calcin have been observed in some patients, suggesting
greater importance of bone resorption compared with
bone formation in this disorder [21]. Although histology
reveals increased osteoclasts in early CRMO lesions [8],
and early radiographs reveal osteolysis, we were not able
to show generalized increase in bone resorption markers
or in markers of bone formation compared to age-specific
norms. Four patients had baseline uNTX/uCr values
above the 75th % percentile for age, but we feel that this
increase most likely reflects the on-set of puberty, rather
than increase from CRMO related osteolysis. All patients
had a decrease in uNTX/uCr following pamidronate,
which was expected. However, while it is also expected
that uNTX/uCr values gradually begin to increase after
bisphosphonates are discontinued, it is interesting that no
patient relapsed while his/her bone turnover remained
suppressed. It is therefore tempting to speculate that bone
and adjacent soft tissue inflammation may require func-
tioning osteoclasts for clinical manifestations. However,
further studies are required on the role of osteoclasts and
on the potential use of uNTX/uCr in pediatric CRMO.
In long-term studies 20–30% of CRMO patients may
develop acne, psoriasis, synovitis, inflammatory bowel
disease and/or ankylosing spondylitis [3,5,36]. The low
rate of these associations in our patients most likely
reflects the well documented lag in presentation of the
extra-osseous manifestations, and their true incidence will
only become apparent with longer follow-up.
Similar to other reviews of pamidronate in CNO, the only
observed side-effect in our study was transient acute phase
response with the first pamidronate dose [4]. Osteonecro-
sis of the jaw (ONJ) has emerged as a potential concern
for adult patients treated with bisphosphonates. ONJ is in
most cases initiated by tooth removal, and most reported
cases have had a history of malignancy [37]. To date, ONJ
has not been reported in pediatric patients [23,37]. A
comprehensive review by Malmgren et al of all 64 pediat-
ric osteogenesis imperfecta patients in Sweden who were
treated with pamidronate from 1991–2005 revealed no
cases of ONJ. A total of 38 dental surgical procedures were
performed in 22 of these 64 patients at the age of 3.4–31.9
years after 0.03–7.9 years of treatment [37]. However,
until more pediatric data is collected, we suggest the fol-
lowing: 1) a thorough dental assessment pre-pamidro-
nate; 2) wisdom tooth extraction pre-pamidronate in
adolescent patients if recommended by a dentist; and 3)
postponement of dental braces or elective dental extrac-
tions for at least 6 months following the final pamidonate
treatment.Pediatric Rheumatology 2009, 7:2 http://www.ped-rheum.com/content/7/1/2
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The "minimum effective dose" and ideal duration of
pamidronate treatment for CRMO is not known. In this
case series pamidronate was used only when conventional
treatment was ineffective, and symptoms were of long
standing. A much lower dose of pamidronate was
required for MRI documented CRMO resolution follow-
ing relapse, suggesting that early CRMO may be more
amenable to bisphosphonate treatment than persistent
disease. Pamidronate was discontinued once MRI abnor-
malities had resolved. At that time, uNTX/uCr remained
suppressed, and ongoing pamidronate treatment would
not have likely offered additional benefit. However, our
experience as well as that of others [4,28] suggests that
many pediatric CRMO/CNO patients who are treated
with pamidronate eventually flare. We have restricted
repeat treatment to those patients who have MRI con-
firmed relapse of bone inflammation, and whose flare is
unresponsive to NSAIDs.
Finally, pamidronate has been the only intravenous
bisphosphonate available for pediatric patients. However,
other intravenous bisphosphonates are becoming availa-
ble for this age group, including zoledronic acid, which,
because of its higher relative potency [38], may achieve
the same effect as pamidronate with less number of infu-
sions and possibly longer time interval until relapse.
Conclusion
Persistent CRMO, comprising up to 25% of all pediatric
cases [2], continues to be a management challenge due to
intractable pain, and risk for permanent bone deformities.
In this sub-group of patients, potential advantages of
pamidronate include rapidity of symptom control and
improvement in quality of life. It is not yet known
whether improvement in bone inflammation following
pamidronate will result in decreased bone deformities in
future. However, although our results are encouraging,
they are uncontrolled and observational. There is now a
great need for a randomized controlled trial, with partici-
pation of many centers, to help define the place of
bisphosphonates in the management of pediatric CRMO
and other CNO disorders.
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